基础研究
Copyright ©The Author(s) 2024.
世界华人消化杂志. 2024-08-28; 32(8): 608-615
在线出版 2024-08-28. doi: 10.11569/wcjd.v32.i8.608
表1 35例胃癌患者的临床资料
临床参数n
年龄<6017
≥6018
性别Male19
Female16
临床分期Ⅰ-Ⅱ20
Ⅲ-Ⅳ15
肿瘤大小<5 cm23
≥5 cm12
表2 胃癌组织中circRASSF2和miR-218-5p的表达
分组ncircRASSF2miR-218-5p
癌旁组织350.87±0.191.15±0.14
胃癌组织352.28±0.32a0.58±0.09a
t22.41420.261
P<0.05<0.05
表3 胃癌细胞中circRASSF2和miR-218-5p的表达
分组ncircRASSF2miR-218-5p
GES-191.00±0.001.00±0.00
HGC-2791.87±0.05a0.35±0.11a
AGS92.31±0.21a0.17±0.08a
t37.56050.455
P<0.05<0.05
表4 双荧光素酶报告实验结果(mean±SD, n = 9)
分组wt-circRASSF2mut-circRASSF2
HGC-27miR-NC1.01±0.070.97±0.07
miR-218-5p0.41±0.05a1.03±0.07
AGSmiR-NC1.00±0.111.02±0.09
miR-218-5p0.52±0.06a0.98±0.08
t20.9251.818
P<0.050.088
表5 circRASSF2调控miR-218-5p的表达(mean±SD, n = 9)
分组miR-218-5p
HGC-27si-NC1.00±0.00
si-circRASSF23.22±0.11a
AGSsi-NC1.02±0.12
si-circRASSF22.53±0.23a
t60.545
P<0.05
表6 circRASSF2和miR-218-5p影响细胞抑制率和克隆形成(mean±SD, n = 9)
分组抑制率/%克隆形成数/个凋亡率/%迁移细胞数/个
HGC-27si-NC0.00±0.00112.52±6.258.07±0.47169.89±10.80
si-circRASSF255.23±2.34a40.27±3.36a22.89±1.15a73.00±2.54a
miR-NC0.03±0.03101.40±9.338.11±0.57171.00±11.17
miR-218-5p mimic44.19±2.70b42.26±4.11b19.78±1.13b85.78±3.91b
si-circRASSF2+anti-miR-NC55.01±2.7537.21±3.3823.06±1.3669.56±3.47
si-circRASSF2+miR-218-5p Inhibitor20.36±1.22c89.27±8.25c13.31±0.79c146.44±7.26c
AGSsi-NC0.00±0.0055.26±6.425.64±0.67116.51±12.14
si-circRASSF243.84±5.77a24.33±2.27a18.96±1.52a56.58±6.36a
miR-NC0.01±0.0246.28±4.184.98±0.58113.84±12.21
miR-218-5p mimic45.26±5.10b18.22±2.14b19.27±2.21b52.27±5.95b
si-circRASSF2+anti-miR-NC44.1±4.519.33±1.7419.04±2.0257.43±6.27
si-circRASSF2+miR-218-5p Inhibitor18.62±1.92c40.39±3.85c9.25±0.97c101.22±10.61c
F1569.442375.574429.625379.610
P<0.05<0.05<0.05<0.05

引文著录: 骆超, 朱迪, 陈跃华. CircRASSF2靶向miR-218-5p调控胃癌细胞增殖、迁移和凋亡的研究. 世界华人消化杂志 2024; 32(8): 608-615